FarmaKeio publishes a patient monograph describing a compounded NAD+ injection supplied as a premixed liquid for subcutaneous use. The document is useful evidence that the pharmacy provides information about this preparation, but it is not a complete consumer subscription offer or a current stock confirmation for every patient.
We reviewed the publicly hosted monograph on September 19, 2026. We did not order medication, test a vial, or verify a clinic’s supplier relationship. This review focuses on the document’s practical value and the additional information needed to understand an individual prescription.
FarmaKeio’s monograph is a patient-information source, not a complete treatment offer. Confirm the actual pharmacy label, care arrangement, and price with the prescriber and pharmacist.
What the monograph confirms
The FarmaKeio NAD+ injection PDF describes a premixed injectable preparation and includes patient-use information. That differs from a lyophilized product requiring a preparation step. The document does not, by itself, identify every strength, vial size, or supplied quantity available for a particular prescription.
Ask the pharmacist to confirm the formulation and label that would accompany your order. Our label-reading guide explains which details need to be understood together. A generic monograph should not be used to calculate a personal schedule or to substitute for directions tied to the actual medication.
The listed uses are not approval statements
The document lists several contexts in which NAD+ may be prescribed. Such a list does not establish FDA-approved indications or demonstrate that FarmaKeio’s finished preparation effectively treats each condition named. A prescriber should explain the evidence and clinical reasoning for the specific use being proposed to you.
Our NAD+ evidence review separates biological research from demonstrated outcomes with a particular formulation. If you are seeking help for a diagnosed condition, discuss established care and alternatives rather than treating a supplier document as a recommendation. A product can have patient information without having strong evidence for every advertised goal.
A supplier is not the same as a care program
FarmaKeio’s monograph does not establish which clinician evaluates a patient, what visits are included, or how medical follow-up is arranged. Those responsibilities may belong to a separate clinic or telehealth service. Ask the service to explain who makes prescribing decisions and who monitors the treatment after dispensing.
Also identify the pharmacy contact for storage, label, or quality questions. The consultation checklist can help record each organization’s role. A recognizable supplier name should make the medication easier to investigate, not obscure the identity of the clinician responsible for your care.
Confirm handling instructions for the actual order
The monograph contains general use and safety information, but the dispensed label should establish the preparation-specific directions and usable dates. Ask what to do if the vial, packaging, or instructions differ from what was expected. Do not decide that a changed product can be used with the previous shipment’s instructions.
For delivery, get a clear process for a delayed or damaged parcel and for questions about storage conditions. Our pharmacy verification guide helps organize those checks. We did not inspect a shipment or authenticate a batch record, so this review does not certify the quality of any individual vial.
Obtain the complete financial picture
We did not establish a current all-in patient price from the monograph. A clinical service may charge for evaluation, medication, supplies, shipping, and ongoing access, and those components can vary independently. Ask whether a quoted amount buys a vial, a defined supply period, or a broader care plan.
The cost guide explains why pharmacy and telehealth prices should not be mixed without context. Also ask how refill changes or a clinician-directed stop affect payment. A supplier PDF cannot answer the cancellation and refund terms of the separate service that arranged the prescription.
Where FarmaKeio fits in a pharmacy comparison
For other patient-information approaches, see Belmar Pharma Solutions. For premixed catalog entries, compare Hallandale Pharmacy and MediVera. These reviews help identify differences in documentation and formulation; they do not establish equivalent preparations or better clinical outcomes.
Our CoreAge Rx review covers the featured commercial partner at the service level and does not imply FarmaKeio is its supplier. The useful next step when this pharmacy is named is to confirm the actual label, prescribing arrangement, and complete quote. That is a stronger basis for a decision than a general monograph alone.
Follow the source
References & further reading
- FarmaKeio — NAD+ injection patient monograph
Checked September 19, 2026. Public PDF in a 2025 document path. Listed uses are not FDA-approved indications or current stock confirmation.
- FDA — compounding questions and answers
Compounded drugs are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality.
- FDA — ingredients suitable for sterile compounding
Reports NAD+ injectable adverse events and ingredient-quality concerns.
- Grant et al. (2019) — human NAD+ infusion pilot
Small IV metabolism study; does not establish benefits of home injections.